All In Biotech

Drug Trial Radar · NCT03531320

Study of D07001-Softgel Capsules in Subjects With Gastrointestinal Cancer in Dose-Escalation Phase and in Subjects With Biliary Tract Cancer in Dose-Expansion Phase

Open-Label, Multicenter Study of D07001-Softgel Capsules (Oral Gemcitabine Hydrochloride) in Subjects With Unresectable, Metastatic or Locally Advanced Gastrointestinal (GI) Cancer in Dose-Escalation Phase and in Subjects With Advanced Biliary Tract Cancer (BTC) Following Primary Chemotherapy or Combined Chemoradiotherapy (CCRT) in Dose-Expansion Phase

Last checked: Nov 20, 2026Latest source record: Nov 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

19

Actual

Start

Aug 6, 2018

Primary completion

Dec 28, 2020

Study completion Dec 29, 2020

Sponsor

Lead sponsor
InnoPharmax Inc.Industry
Sponsor type
Industry
First posted
May 21, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Part 1: Dose-Escalation Phase (Phase 1b) The primary objective is to assess the safety and tolerability of increasing doses of D07001 softgel in patients with unresectable locally advanced or metastatic gastrointestinal (GI) cancer. Part 2: Dose-Expansion Phase (Phase 2) The primary objective is to assess the safety and tolerability of D07001 softgel in patients who have achieved stable disease or better following first line chemotherapy or combined chemoradiotherapy (CCRT) for unresectable metastatic or locally advanced biliary tract cancer (BTC)

Conditions

  • Gastrointestinal Cancer
  • Biliary Tract Cancer

Interventions

  • D07001-softgel capsulesDrug

    Active Ingredient:Gemcitabine hydrochloride

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Establish the Maximum Tolerated Dose (MTD)Time frame: During Cycle 1 of treatment (each cycle is 21 days) for each subject
  2. Part 1 : Incidence of Adverse Events (AEs)/ Serious Adverse Event (SAEs)Time frame: From date of informed consent to 30-day follow-up visit for each subject, an average of 10 months
  3. Part 2: Incidence of Dose Modifications, Including Dose Reduction, Interruption, or Discontinuation of Study DrugTime frame: First dose through last dose for each subject, an average of 8 months

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • China Medical University Hospital

    Taichung, Taiwan

  • National Cheng-Kung University Hospital

    Tainan, Taiwan

  • National Taiwan University Hospital

    Taipei, Taiwan

  • Taipei Veterans General Hospital

    Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.